Lung Ultrasound in Pediatric Acute Respiratory Distress Syndrome Received Extracorporeal Membrane Oxygenation: A Prospective Cohort Study

Yucai Zhang1,2*, Chunxia Wang1,2,†‡, Fei Wang1, Jingyi Shi1, Jiaying Dou1,2, Yijun Shan1, Ting Sun1 and Yiping Zhou1

1 Department of Critical Care Medicine, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai, China, 2 Institute of Pediatric Critical Care, Shanghai Jiao Tong University, Shanghai, China, † Clinical Research Unit, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai, China

Objectives: The aim of this study was to assess the prognostic value of the lung ultrasound (LUS) score in patients with pediatric acute respiratory distress syndrome (pARDS) who received extracorporeal membrane oxygenation (ECMO).

Methods: A prospective cohort study was conducted in a pediatric intensive care unit (PICU) of a tertiary hospital from January 2016 to June 2021. The severe pARDS patients who received ECMO were enrolled in this study. LUS score was measured at initiation of ECMO (LUS-0 h), then at 24 h (LUS-24 h), 48 h (LUS-48 h), and 72 h (LUS-72 h) during ECMO, and when weaned from ECMO (LUS-wean). The value of LUS scores at the first 3 days of ECMO as a prognostic predictor was analyzed.

Results: Twenty-nine children with severe pARDS who received ECMO were enrolled with a median age of 26 (IQR 9, 79) months. The median duration of ECMO support was 162 (IQR 86, 273) h and the PICU mortality was 31.0% (9/29). The values of LUS-72 h and LUS-wean were significantly lower in survivors than that in non-survivors (both \( P < 0.001 \)). Daily fluid balance volume during the first 3 days of ECMO support were strongly correlated with LUS score [1st day: \( r = 0.460, P = 0.014 \); 2nd day: \( r = 0.540, P = 0.003 \); 3rd day: \( r = 0.589, P = 0.001 \)]. The AUC of LUS-72 h for predicting PICU mortality in these patients was 1.000, and the cutoff value of LUS-72 h was 24 with a sensitivity of 100.0% and a specificity of 100.0%. Furthermore, patients were stratified in two groups of LUS-72 h \( \geq 24 \) and LUS-72 h \( < 24 \). Consistently, PICU mortality, length of PICU stay, ratio of shock, vasoactive index score value, and the need for continuous renal replacement therapy were significantly higher in the group of LUS-72 h \( \geq 24 \) than in the group of LUS-72 h \( < 24 \) (all \( P < 0.05 \)).

Conclusion: Lung ultrasound score is a promising tool for predicting the prognosis in patients with ARDS under ECMO support. Moreover, LUS-72 h \( \geq 24 \) is associated with high risk of PICU mortality in patients with pARDS who received ECMO.

Keywords: lung ultrasound (LUS) score, acute respiratory distress syndrome, extracorporeal membrane oxygenation, prognosis, children
INTRODUCTION

The mortality of severe acute respiratory distress syndrome (ARDS) patients was 33% (95% CI: 26–41) according to an international prospective study covering 145 pediatric intensive care units (PICUs) from 27 countries (1). The Pediatric Acute Lung Injury Consensus Conference (PALICC) recommended that extracorporeal membrane oxygenation (ECMO) should be considered to support children with severe pediatric ARDS (pARDS) when lung protective strategies result in inadequate gas exchange (2). Until now, ECMO has become increasingly usual for severe pARDS due to improvement in technology and deeper understanding about indications and contraindications (3, 4). However, it is still challenging to optimize management of ECMO, which is critical for reducing adverse events and ECMO-related complications. Developing convenient and non-invasive tools and methods will lead to a promising view for delicacy management of ECMO.

Extravascular lung water (EVLW) identified in patients with non-cardiogenic pulmonary edema reflects the severity of ARDS and could be detected by a pulse indicator continuous cardiac output (PiCCO2), but it is not convenient for pediatric patients (5, 6). Besides, lung computed tomography (CT) is regarded as the gold standard for non-invasive evaluation of pulmonary edema; however, exposure to ionizing radiation and transportation of the critically ill limit its application, especially in children (7). Lung ultrasound (LUS) is a non-invasive, radiation-free, and bedside tool for management of the critically ill. LUS score was proved to be an alternative method for monitoring pulmonary edema and may guide management strategies for ARDS in both adults and children (8–10). Moreover, LUS score or the number of LUS B-lines predicts the outcomes in acute heart failure or interstitial lung disease (11, 12). Until now, the value of LUS score in predicting the prognosis in patients with pARDS under ECMO support has not been systematically studied.

In this study, children with pARDS who received ECMO were prospectively enrolled, and LUS score was determined before and during ECMO support. We aimed to evaluate the potential value of LUS score as an accurate and easy method to predict the prognosis of these children with ECMO support.

Abbreviations: AKI, acute kidney injury; AUC, area under the curve; BMI, body mass index; Cdyn, dynamic lung compliance; CI, confidence interval; CRRT, continuous renal replacement therapy; CT, computed tomography; DIC, disseminated intravascular coagulation; ECMO, extracorporeal membrane oxygenation; ELSO, extracorporeal life support organization; EVLW, extravascular lung water; FiO2, fractional concentration of oxygen in inspired gas; LUS, lung ultrasound; MAP, mean airway pressure; MODS, multiple organ dysfunction syndrome; OI, oxygen index; PF ratio, PaO2/FiO2 ratio; pARDS, pediatric acute respiratory distress syndrome; PEEP, positive end-expiratory pressure; PALICC, The Pediatric Acute Lung Injury Consensus Conference; PiCCO2, pulse indicator continuous cardiac output; PICU, pediatric intensive care unit; PIP, positive inspiration pressure; PRISM III, pediatric risk mortality III; ROC, receiver operating characteristic; VA-ECMO, veno-arterial extracorporeal membrane oxygenation; VV-ECMO, veno-venous extracorporeal membrane oxygenation; VIS, vasoactive index score.

MATERIALS AND METHODS

Study Design and Patient Populations

A prospective cohort study was conducted in a 36-bed PICU of a tertiary-level teaching hospital (Shanghai Children’s Hospital, Shanghai Jiao Tong University, China). Our study was approved by the Ethics Committee of the hospital (Approval number: 2016R011-E02). All patients’ parents or relatives signed informed consent and agreed with ECMO support and LUS measurement, as well as enrolling patients in this study. Our ECMO center is one of the major ECMO centers for children in China, which has been registered at the Extracorporeal Life Support Organization (ELSO) (No. 663).

Patients with pARDS who received ECMO during PICU hospitalization were enrolled from January 2016 to June 2021. The pARDS is defined according to the 2015 PALICC definition of ARDS (2). Inclusion criteria included: (1) aged over 28 days to 14 years; and (2) the interval time between ARDS diagnosis and ECMO initiation less than 7 days. Exclusion criteria included: (1) ECMO duration was less than 3 days; (2) lack of appropriate acoustic window for LUS determination; (3) complicated with pneumothorax; (4) complicated with congenital heart disease; and (5) complicated with chronic lung disease (Figure 1). Patients with ARDS complicated with pneumothorax or chronic lung disease could receive ECMO as a rescued therapy. However, pneumothorax or chronic lung disease would lead to inaccurate measures about the LUS score, so these patients were excluded in this study.

Data Collection

Demographics, comorbidities, complications, and outcomes were collected according to a pre-designed case report form (CRF). Demographics data included age, gender, and body mass index (BMI). The pediatric risk mortality III (PRISM III) score and comorbidities were determined at ECMO initiation. Clinical parameters included oxygen in inspired gas (FiO2), PaO2/FiO2 (PF ratio), oxygen index (OI), PaCO2, and Cdyn, which was calculated by ventilators (MAQUET Company, Servo-i serious), required ECMO blood flow and gas flow. The outcomes included PICU mortality, length of PICU stay, duration of ECMO, duration of ventilation, complications, and adverse events related to ECMO support.

Ventilation Before Extracorporeal Membrane Oxygenation

Ventilation settings after patients meeting the diagnosis of pARDS complied with lung protective ventilation strategy, were positive end-expiratory pressure (PEEP) levels of 8–15 cmH2O and positive inspiration pressure (PIP) levels based on target tidal volume (Vt) of 4–8 ml/kg but less than 35 cmH2O (2).

Extracorporeal Membrane Oxygenation and Mechanical Ventilation

Extracorporeal membrane oxygenation should be considered to support children with severe pARDS in whom the cause of the
respiratory failure is reversible, or who is likely to be suitable for lung transplantation, or when lung protective strategies result in inadequate gas exchange; otherwise, ECMO should not be deployed in patients in whom life-sustaining measures are likely to be limited (13). In our center, we also referred to the adult-related ECMO indications [according to the guidelines from the ELSO Website outlined (14)] including: (1) PF ratio < 60–80 mmHg or OI > 40; (2) mean airway pressure (MAP) > 20–25 cmH\textsubscript{2}O on conventional ventilation; (3) evidence of iatrogenic barotrauma; (4) acute unremitting hypercapnic or hypoxic respiratory failure; (5) air leak syndrome; (6) mediastinal masses; and (7) cardiac failure. The contraindications for ECMO are (14): (1) lethal chromosomal abnormalities (trisomy 13 or 18); (2) severe neurologic compromise (intracranial hemorrhage with mass effect); and (3) incurable malignancy. The ECMO mode (ECMO machine: rotaflow, MAQUET Cardiopulmonary GmbH, Germany) included veno-arterial (VA) ECMO for complication with cardiac failure or hemodynamically unstable, and veno-venous (VV) ECMO for respiratory failure using a membrane lung. While native lung function supports adequate ventilation and oxygenation, weaning from VV-ECMO in patients requires cessation of gas-exchange support across the membrane oxygenator; and if adequate ventilation, oxygenation, and hemodynamic stability can be attained with a trial at low flow or no flow, patients could be separated from the VA-ECMO circuit (13). The adult-related indications for ECMO weaning were used as a reference in our center which included the following (14): The ABG was normal when fractional concentration of FiO\textsubscript{2} was less than 0.5, PIP was less than 25 cmH\textsubscript{2}O, Cdyn was greater than 0.5 ml/kg.cmH\textsubscript{2}O, and required blood flow was less than 10 ml/kg, and required gas flow had been closed for more than 6 h.

The catheterization for ECMO was usually determined by the body weight of patients. In the present study, the VV-ECMO cannulae (Medtronic Bio-Medicus) were inserted through the right internal jugular vein and right femoral vein. For VA-ECMO, cannulae (Medtronic Bio-Medicus) were inserted through the right femoral artery and the right femoral vein in children with body weight over or equal to 15 kg; and ECMO cannulae (Medtronic Bio-Medicus) were inserted through the right internal carotid artery and right internal jugular vein through surgical incisions if the body weight of the patient was less than 15 kg.

Ventilation parameters during ECMO support according to the suggestion from ELSO guidelines (14) included low rate, long inspiratory time, PIP less than 25 cmH\textsubscript{2}O, FiO\textsubscript{2} less than 0.4, and PEEP set at an appropriate level for patient condition.

**Lung Ultrasound Score**

Lung ultrasound score was measured at the initiation of ECMO as the value of LUS-0 h. Then, the values were measured every morning in the following 3 days and at the termination of ECMO as LUS-24 h, LUS-48 h, LUS-72 h, and LUS-wean, respectively (Figure 1). For each of the LUS scores determined, corresponding ventilator and ECMO parameters were also recorded. LUS was performed by a PICU attending physician (independent scorer) who underwent a standard training. A 13–6 MHz curvilinear probe perpendicularly on the chest wall checks all intercostal spaces clearly (ultrasonography machine: M-Turbo Ultrasound System, Mini-Dock-M Series, SonoSite). Each hemithorax was divided into anterior, lateral, and posterior region according to the sternum, paravertebral, anterior, and posterior axillary lines, and each region was divided into superior and inferior halves (Supplementary Figure 1). All intercostal spaces of 12 areas were...
examined sequentially in supine, lateral, and prone positions. Each image should identify pleura lines and A-line. The scoring system in the present study is as described by Brat et al. (15).

Statistical Analysis
All data were analyzed using SPSS 17.0 statistics (SPSS Inc., Chicago, IL, United States). Univariate comparisons of proportions were compared with chi-square tests. The continuous data with non-parametric distribution were expressed as median (interquartile range, IQR) and compared using the Mann-Whitney U test. The Friedman ANOVA was used to compare LUS score and Cdyn at 5 different time points during ECMO support (0 h, 24 h, 48 h, 72 h, and wean). The correlation between LUS scores and the change of daily fluid balance during the first 3 days after ECMO initiation were performed using a Bonferroni correction. All P values were two-sided and statistical significance was taken as \( P < 0.05 \).

RESULTS
Baseline Characteristics of Patients With Pediatric Acute Respiratory Distress Syndrome Who Received Extracorporeal Membrane Oxygenation
A total of 185 patients with moderate to severe pARDS were admitted to a PICU from January 2016 to June 2021. Among them, 43 cases with severe pARDS received ECMO. According to the exclusion criteria, 1 case with less than 3 days ECMO duration, 3 cases with lack of appropriate acoustic window, 5 cases with pneumothorax, 4 cases with congenital heart disease, TABLE 1 | Baseline characteristics of patients at initiation of ECMO support.

| Characteristics | Total (n = 29) | Survivors (n = 20) | Non-survivors (n = 9) | P-value |
|-----------------|---------------|--------------------|-----------------------|---------|
| Age, month, IQR| 26 (9–79)     | 37 (12–72)         | 15 (4–91)             | 0.383   |
| Male, n (%)     | 14 (48.3)     | 8 (40.0)           | 6 (66.7)              | 0.184   |
| PRISM III       | 18 (14–22)    | 17 (13–21)         | 25 (14–35)            | 0.093   |
| BMI, kg/m²      | 14 (13–16)    | 14 (13–15)         | 16 (14–19)            | 0.109   |
| Lactate, mmol/L, IQR | 1.5 (0.7–4.3) | 1.2 (0.5–2.3) | 3.7 (0.7–8.0)         | 0.245   |
| Primary lung disease, n (%) | 24 (82.8) | 16 (80.0) | 8 (88.9) | 0.558 |
| Comorbidity     |               |                    |                       |         |
| Leucocytokemia, n (%) | 2 (6.9) | 1 (5.0) | 1 (11.1) | 0.548   |
| Tumor, n (%)    | 2 (6.9)       | 0 (0)              | 2 (22.2)              | 0.029   |
| Autoimmune system diseases, n (%) | 1 (3.4) | 1 (5.0) | 0 (0) | 0.495 |
| Neuromuscular disease, n (%) | 1 (3.4) | 1 (5.0) | 0 (0) | 0.495 |
| Complication    |               |                    |                       |         |
| Shock, n (%)    | 22 (75.9)     | 13 (65.0)          | 9 (100.0)             | 0.042   |
| AKI, n (%)      | 16 (55.2)     | 8 (40.0)           | 8 (88.9)              | 0.014   |
| Hepatic dysfunction, n (%) | 9 (31.0) | 5 (25.0) | 4 (44.4) | 0.295 |
| Gastrointestinal dysfunction, n (%) | 6 (20.7) | 3 (15.0) | 3 (33.3) | 0.260 |
| MODS, n (%)     | 15 (51.7)     | 8 (40.0)           | 7 (77.8)              | 0.060   |
| Baseline at ECMO initiation | | | | |
| LUS score, IQR | 28 (27–30)    | 28 (27–30)         | 29 (28–30)            | 0.427   |
| PaO₂/FiO₂, mmHg, IQR | 60 (55–68) | 63 (56–68) | 60 (51–64) | 0.227 |
| OI, IQR         | 32 (28–41)    | 31 (27–37)         | 41 (32–43)            | 0.073   |
| PaCO₂, mmHg, IQR | 52 (43–65) | 52 (44–60) | 61 (34–75) | 0.533 |
| Cdyn, ml/cmH₂O.kg, IQR | 0.33 | 0.34 | 0.33 | 0.758 |
| (0.30–0.39)     | (0.30–0.40)   | (0.30–0.38)        |                       |         |
| Mechanical ventilation settings | | | | |
| PIP, cmH₂O, IQR | 29 (28–32)    | 30 (28–32)         | 29 (28–31)            | 0.651   |
| PEEP, cmH₂O, IQR | 12 (10–13) | 13 (12–14) | 13 (12–15) | 0.278 |
| FiO₂, %, IQR    | 100 (100–100) | 100 (100–100) | 100 (100–100) | 0.334 |
| Mode of ECMO    |               |                    |                       |         |
| VA-ECMO, n (%)  | 21 (72.4)     | 13 (65.0)          | 8 (88.9)              | 0.183   |
| WV-ECMO, n (%)  | 8 (27.6)      | 7 (35.0)           | 1 (11.1)              | 0.183   |

LUS, lung ultrasound; ECMO, extracorporeal membrane oxygenation; VA-ECMO, veno-arterial extracorporeal membrane oxygenation; WV-ECMO, veno-venous extracorporeal membrane oxygenation; PaO₂/FiO₂, PaO₂/FiO₂ ratio; PEEP, positive end-expiratory pressure; AKI, acute kidney injury; MODS, multiple organ dysfunction syndrome; PIP, positive inspiration pressure; Cdyn, dynamic lung compliance; PRISM III, pediatric risk mortality III; FiO₂, fractional concentration of oxygen in inspired gas; BMI, body mass index.
and 1 case with chronic lung disease were excluded. Finally, 29 patients were ultimately entered into analysis in this study. The median age of these patients was 26 (IQR, 9–79) months, and there were 14 male patients (48.3%, 14/29). Among 29 patients, 20 children survived and 9 children died. There were no significant differences in aspects of age, gender, PRISM III score, respiratory parameters, ventilator settings, and mode of ECMO between survivors and non-survivors (all P > 0.05) (Table 1).

**Lung Ultrasound Score, Respiratory System Compliance, and Daily Fluid Balance During Extracorporeal Membrane Oxygenation Between Survivors and Non-survivors**

There were no differences about the values of LUS-0 h, LUS-24 h, and LUS-48 h between survivors and non-survivors (all P > 0.05); however, the values of LUS-72 h and LUS-48 h were significantly lower in survivors than in non-survivors (both P < 0.001) (Table 2). In addition, the degree of negative fluid balance of the 2nd day (48–24 h) or 3rd day (72–48 h) after ECMO support was greater in survivors than in non-survivors (P = 0.032 and P = 0.007, respectively) (Table 2).

The value of LUS-0 h was 28 (IQR, 27–30), and then gradually decreased to 22 (IQR, 20–23) of LUS-72 h in the survival group (<P>0.001), but there was no significant decrease in the non-survival group (Table 2). In addition, the value of Cdyn was 0.35 (IQR, 0.30–0.38) ml/cmH$_2$O.kg at 48 h after ECMO support, then gradually increased to 0.66 (IQR, 0.63–0.70) ml/cmH$_2$O.kg when weaned from ECMO in the survival group (P < 0.001). However, the change of Cdyn was gradually decreased from 0.31 (IQR, 0.29–0.36) ml/cmH$_2$O.kg of LUS-48 h to 0.26 (IQR, 0.16–0.32) ml/cmH$_2$O.kg of LUS-wean in the non-survival group (P = 0.012) (Table 2). Moreover, both required blood flow and required gas flow had significant reduction from 48 h after ECMO support to ECMO weaning in the survival group (Table 2).

Lung ultrasound scores of all the distribution regions during the first 72 h of ECMO support were not significantly decreased in the non-survival group (Figure 2A). In the survival group, the LUS scores of bilateral anterior, lateral, and posterior regions were all significantly improved during the first 72 h of ECMO support (all P < 0.01). Moreover, all the peak values of LUS score in anterior, lateral, and posterior regions were displayed at 24 h after ECMO support, then the values of the LUS score in the anterior and lateral regions, but not posterior, were decreased in the survival group (P < 0.05; Figure 2B).

**Correlation of Lung Ultrasound Score, Respiratory Dynamics, and Fluid Balance Volume**

An excellent correlation was observed between LUS score and daily fluid balance during the first 72 h of ECMO treatment (all P < 0.05) (Figure 3A). In addition, LUS score was negatively correlated with Cdyn during ECMO support (all P < 0.05) (Figure 3B).

**Receiver Operating Characteristic Analysis of Lung Ultrasound Score for Prediction of Prognosis in Patients With Pediatric Acute Respiratory Distress Syndrome**

Receiver operating characteristic analysis of significantly changed variables during ECMO support was constructed for predicting PICU mortality, and the value of AUC for LUS-72 h, 3rd day fluid balance-(72–48 h), required ECMO blood flow-72 h, or Cdyn-72 h was 1.000 [95% CI: 1.000–1.000], 0.831 [95% CI: 0.659–1.000], 0.825 [95% CI: 0.653–0.997], or 0.913 [95% CI: 0.748–1.000], respectively (all P < 0.05). Among them, the cutoff value of LUS-72 h for predicting PICU mortality was 24 with a sensitivity of 100% and a specificity of 100%, respectively (Table 3).

**Table 2** Comparison of LUS score, respiratory compliance, and daily fluid balance during ECMO between survivors and non-survivors (IQR).

| Parameters          | Survivors (n = 20) | Non-survivors (n = 9) | P-value |
|---------------------|-------------------|----------------------|---------|
| **LUS score**       |                   |                      |         |
| 0 h                 | 28 (27–30)        | 29 (28–30)           | 0.427   |
| 24 h                | 31 (29–31)        | 31 (30–32)           | 0.219   |
| 48 h                | 27 (26–28)        | 28 (27–30)           | 0.101   |
| 72 h                | 22 (20–23)        | 30 (25–31)           | <0.001  |
| wean                | 12 (10–15)        | 30 (28–34)           | <0.001  |
| **Cdyn, ml/kg.cmH$_2$O** |               |                      |         |
| 0 h                 | 0.38 (0.30–0.40)  | 0.35 (0.32–0.37)     | 0.366   |
| 24 h                | 0.32 (0.27–0.35)  | 0.30 (0.27–0.32)     | 0.380   |
| 48 h                | 0.35 (0.30–0.38)  | 0.31 (0.29–0.36)     | 0.256   |
| 72 h                | 0.44 (0.41–0.55)  | 0.35 (0.28–0.38)     | <0.001  |
| wean                | 0.66 (0.63–0.70)  | 0.26 (0.16–0.32)     | <0.001  |
| **Required ECMO blood flow, ml/kg.min** |       |                      |         |
| 0 h                 | 87 (74–92)        | 83 (74–108)          | 0.799   |
| 24 h                | 76 (65–86)        | 90 (62–104)          | 0.285   |
| 48 h                | 60 (63–103)       | 97 (62–132)          | 0.524   |
| 72 h                | 62 (43–76)        | 85 (74–111)          | 0.008   |
| wean                | 11 (8–29)         | 78 (12–135)          | 0.023   |
| **Required ECMO gas flow, L/min** |       |                      |         |
| 0 h                 | 2.0 (1.3–2.0)     | 1.8 (1.0–3.1)        | 0.481   |
| 24 h                | 1.4 (1.0–2.0)     | 1.6 (0.8–3.1)        | 0.609   |
| 48 h                | 1.7 (0.9–2.0)     | 1.3 (0.8–3.4)        | 0.759   |
| 72 h                | 1.5 (1.0–2.0)     | 1.3 (0.6–3.9)        | 0.979   |
| wean                | 0.0 (0–0.4)       | 1.8 (0–2.5)          | 0.042   |
| **Daily fluid balance volume, ml/kg.d** |       |                      |         |
| 24–0 h              | 17 (12–22)        | 21 (17–30)           | 0.202   |
| 48–24 h             | −16 [−18–−12]     | −11 [−12–−8]         | 0.032   |
| 72–48 h             | −12 [−14–−8]      | −6 [−9–−4]           | 0.007   |

LUS, lung ultrasound; ECMO, extracorporeal membrane oxygenation; Cdyn, dynamic lung compliance.
### TABLE 3 | Receiver operating characteristic analysis of variables for predicting PICU mortality.

| Parameters                        | AUC         | 95% CI        | Cutoff | Sensitivity(%) | Specificity(%) | P-value |
|-----------------------------------|-------------|---------------|--------|----------------|----------------|---------|
| LUS-72 h                          | 1.000       | (1.000–1.000) | 24     | 100.0          | 100.0          | 0.000   |
| Fluid balance-(48–24 h)           | 0.763       | (0.532–0.993) | –13    | 87.5           | 75.0           | 0.033   |
| Fluid balance-(72–48 h)           | 0.831       | (0.659–1.000) | –7     | 75.0           | 90.0           | 0.007   |
| Required ECMO blood flow -72 h (ml/min) | 0.825     | (0.653–0.997) | 76.3   | 62.5           | 80.0           | 0.008   |
| 1/Cdyn-72 h                       | 0.913       | (0.748–1.000) | 2.74   | 87.5           | 100.0          | 0.001   |

LUS, lung ultrasound; ECMO, extracorporeal membrane oxygenation; Cdyn, dynamic lung compliance; PICU, pediatric intensive care unit; CI, confidence interval; ROC, receiver operating characteristic; AUC, area under the curve.

### DISCUSSION

Lung monitoring is crucial for evaluation of treatment effectiveness and early identification of complications in patients with ARDS (16). In this prospective cohort study, we monitored the changes of LUS score in 29 patients with pARDS during ECMO support, and the main findings are as follows: (1) patients with LUS-72 h ≥ 24 have a higher risk of PICU mortality; and (2) LUS score is correlated to daily fluid balance volume and the value of Cdyn. These results give us new insight into the tool for monitoring the severity of pulmonary edema during ECMO support.
extracorporeal life support. Fluid balance is associated with the temporary deterioration inflammatory response by early ECMO support (within 24 h), which could be related to the activation of coagulation inflammation, which is involved in the recovery of pulmonary function. Prat et al. reported that regional changes of LUS could be a tool in prediction of prone positioning oxygenation response in ARDS patients (30). In our study, LUS score was correlated with Cyd-n-72. Intriguingly, LUS score was used in predicting the outcomes of ARDS caused by COVID-19 (10, 31, 32). In the present study, the LUS scores of posterior regions were highest and improved slowest after ECMO support in the survival group. More importantly, LUS-72 h for predicting PICU mortality is superior to fluid balance-(3rd day, 72–48 h) and Cdyn-72 h. All these results suggest that assessing regional fluid management in the lung could be more important to the recovery of pulmonary function. Prat et al. reported that regional changes of LUS could be a tool in prediction of prone positioning oxygenation response in ARDS patients (30). In our study, LUS score was correlated with Cyd-n-72. Intriguingly, LUS score was used in predicting the outcomes of ARDS caused by COVID-19 (10, 31, 32). In the present study, the LUS scores of posterior regions were highest and improved slowest after ECMO support in the survival group. More importantly, LUS-72 h for predicting PICU mortality is superior to fluid balance-(3rd day, 72–48 h) and Cdyn-72 h. All these results suggest that assessing regional fluid management in the lung could be more important than global fluid management in children under ECMO support. Our results revealed that patients with LUS-72 h ≥ 24 had a higher risk of PICU mortality and longer PICU stay days.

**STUDY LIMITATIONS**

There were several limitations of this study. First, this is a single center study with limited sample size and children aged ≤ 14 years old, and selection bias cannot be ruled out. Second, the lack of LUS scores from 72 h to ECMO weaning is another limitation. Third, we did not analyze the relationship between the LUS score and other methods for determining

### TABLE 4 | Description of clinical outcomes and complications between LUS-72 h ≥ 24 and LUS-72 h < 24.

| Outcomes                     | Total (n = 29) | LUS-72 h ≥ 24 (n = 9) | LUS-72 h < 24 (n = 20) | P-value |
|------------------------------|---------------|----------------------|-----------------------|--------|
| Duration of ECMO, hours, IQR | 162 (86–273)  | 161 (76–367)       | 179 (118–275)         | 0.671  |
| Duration of ventilation, hours, IQR | 286 (149–434)  | 250 (104–611)      | 288 (164–438)         | 0.604  |
| Length of PICU stay, days, IQR | 15 (12–34)  | 11 (6–26)            | 19 (14–35)            | 0.042  |
| PICU mortality, n (%)      | 9 (31.0)     | 9 (100.0)           | 0 (0)                 | <0.001 |
| Shock, n (%)                | 16 (55.2)    | 9 (100.0)           | 7 (35.0)              | 0.001  |
| Need of CRRT, n (%)        | 22 (75.9)    | 9 (100.0)           | 13 (65.0)             | 0.042  |
| VIS, IQR                    | 150 (83–180) | 190 (135–230)       | 115 (10–170)          | 0.015  |
| DIC, n (%)                  | 6 (20.7)     | 3 (33.3)            | 3 (15.0)              | 0.280  |
| Secondary infections, n (%)| 1 (3.4)      | 0 (0)               | 1 (5.0)               | 0.495  |
| Hemolysis, n (%)            | 6 (20.7)     | 3 (33.3)            | 3 (15.0)              | 0.260  |
| Thrombosis, n (%)           | 1 (3.4)      | 0 (0)               | 1 (5.0)               | 0.495  |
| Intracranial hemorrhage, n (%) | 3 (10.3)   | 2 (22.2)            | 1 (5.0)               | 0.159  |
| Gangrene of limbs, n (%)    | 1 (3.4)      | 0 (0)               | 1 (5.0)               | 0.495  |
| MODS, n (%)                 | 19 (65.5)    | 7 (77.9)            | 12 (60.0)             | 0.351  |

LUS, lung ultrasound; ECMO, extracorporeal membrane oxygenation; PICU, pediatric intensive care unit; CRRT, continuous renal replacement therapy; VIS, vasoactive index score; DIC, disseminated intravascular coagulation; MODS, multiple organ dysfunction syndrome.
EVLW like PiCCO\textsubscript{2} due to the difficulty for carrying out PiCCO\textsubscript{2} in pediatric patients. Fourth, the value of LUS score in pediatric patients with ARDS without ECMO was lacking, the potential role of the LUS score in assessing the severity of pediatric ARDS needs further well-designed clinical research. Fifth, the sub-group analysis according to whether patients were in a prone position was not performed, which could be a more interesting clinical research issue. Nevertheless, LUS is a convenient and non-invasive tool for lung monitoring in patients with pARDS under ECMO support. Importantly, LUS-72 h score is significantly associated with PICU mortality, which could be a potential parameter for guiding the management of lung function in these patients. Our findings are worth further investigation to validate the conclusion in a well-designed multicenter study with a larger population.

CONCLUSION

Lung ultrasound score is correlated to daily fluid balance volume and Cdyn. The LUS score $\geq$ 24 at 72 h of ECMO support is associated with a worse outcome of pARDS. LUS can provide a promising tool for lung monitoring in patients with ARDS receiving ECMO.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

REFERENCES

1. Khemani RG, Smith L, Lopez-Fernandez YM, Kwok J, Morzov R, Klein MJ, et al. Paediatric acute respiratory distress syndrome incidence and epidemiology (PARDIE): an international, observational study. *Lancet Respir Med*. (2019) 7:115–28. doi: 10.1016/s2213-2600(18)30344-8
2. Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the pediatric acute lung injury consensus conference. *Pediatr Crit Care Med*. (2015) 16:428–39. doi: 10.1097/pcc.000000000000350
3. Rowan CM, Klein MJ, Hsing DD, Dahmer MK, Spinella PC, Emeriaud G, et al. Early use of adjunctive therapies for pediatric acute respiratory distress syndrome: a PARDIE study. *Am J Respir Crit Care Med*. (2020) 201:1389–97. doi: 10.1164/rrccm.201909-1807OC
4. Barbaro RP, Paden ML, Guner YS, Raman L, Ryerson LM, Alexander P, et al. Pediatric extracorporeal life support organization registry international report 2016. *Asio J*. (2017) 63:456–63. doi: 10.1097/MAI.0000000000000475
5. Tagami T, Ong MEH. Extravascular lung water measurements in acute respiratory distress syndrome: why, how, and when? *Curr Opin Crit Care*. (2018) 24:209–15. doi: 10.1097/MCC.0000000000000503
6. Kushimoto S, Endo T, Yamanouchi S, Kakimoto T, Ishikura H, Kitazawa Y, et al. Relationship between extravascular lung water and severity categories of acute respiratory distress syndrome by the Berlin definition. *Crit Care*. (2013) 17:R132. doi: 10.1186/cc12811
7. Winkler MH, Touw HR, van de Ven PM, Twisk J, Tuinman PR. Diagnostic accuracy of chest radiograph, and when concomitantly studied lung ultrasound, in critically ill patients with respiratory symptoms: a systematic review and meta-analysis. *Crit Care Med*. (2018) 46:e707–14. doi: 10.1097/CCC.0000000000003129
8. Chiumento D, Umbrello M, Serra R, Papa G, Angileri A, Gurgutino M, Formenti P. Global and regional diagnostic accuracy of lung ultrasound compared to CT in patients with acute respiratory distress syndrome. *Crit Care Med*. (2019) 47:1599–606. doi: 10.1097/CCM.0000000000003971
9. Wang F, Wang C, Shi J, Shan Y, Miao H, Sun T, et al. Lung ultrasound score assessing the pulmonary edema in pediatric acute respiratory distress syndrome received continuous hemofiltration therapy: a prospective observational study. *BMC Pulm Med*. (2021) 21:40. doi: 10.1186/s12890-021-01394-w
10. Lichter Y, Topilsky Y, Taieb P, Banai A, Hochstadt A, Merdler I, et al. Lung ultrasound predicts clinical course and outcomes in COVID-19 patients. *Intensive Care Med*. (2020) 46:1873–83. doi: 10.1007/s00134-020-06212-1
11. Fotoh DS, Helal A, Rizk MS, Esaily HA. Serum Krebs von den Lungen-6 and lung ultrasound B lines as potential diagnostic and prognostic factors for rheumatoid arthritis-associated interstitial lung disease. *Clin Rheumatol*. (2021) 40:2689–97. doi: 10.1007/s10067-021-05585-y
12. Palazzuoli A, Ruocco G, Beltrami M, Nuti R, Cleland JG. Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFpEF and HFrEF. *Clin Res Cardiol*. (2018) 107:586–96. doi: 10.1007/s00392-018-1221-7
13. Dalton HJ, Macrane DJ. Pediatric acute lung injury consensus conference group. Extracorporeal support in children with pediatric acute respiratory distress syndrome: proceedings from the pediatric acute lung injury consensus conference. *Pediatr Crit Care Med*. (2015) 16:S111–7. doi: 10.1097/PCC.0000000000000439

ETHICS STATEMENT

This study was approved by the Ethics Committee of Shanghai Children’s Hospital, Shanghai Jiao Tong University, China (Approval number: 2016R011-E02). All patients’ parents or relatives signed informed consent.

AUTHOR CONTRIBUTIONS

YuZ, CW, and FW contributed in writing the manuscript. FW, YiZ, JS, JD, TS, and YS analyzed the patients’ data. FW performed the lung ultrasound and collected the patients’ data. YuZ was responsible for the design of this study. All authors read and approved the final manuscript.

FUNDING

This study was supported by the Science and Technology Commission of Shanghai Municipality (20Y11901300, 20ZR1446 500, and 21Y11902600).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2022.798855/full#supplementary-material

Supplementary Figure 1 | Partition of chest wall in lung ultrasound examination protocol.
25. Ntoumenopoulos G, Buscher H, Scott S. Lung ultrasound score as an indicator of dynamic lung compliance during veno-venous extra-corporeal membrane oxygenation. *Int J Artif Organs.* (2021) 44:194–8. doi: 10.1177/0391398820498870
26. Al-Fares A, Pettenuzzo T, Del Sorbo L. Extracorporeal life support and systemic inflammation. *Intensive Care Med Exp.* (2019) 7(Suppl. 1):46. doi: 10.1186/s40635-019-0249-y
27. Frerou A, Lesouhaitier M, Gregoire M, Uhel F, Gacouin A, Rezine F, et al. Venoarterial extracorporeal membrane oxygenation induces early immune alterations. *Crit Care.* (2021) 25:9. doi: 10.1186/s13054-020-0444-x
28. Lee JH, Won JY, Kim JE, Kim HJ, Jung JS, Son HS. Association between cumulative fluid balance and outcomes in acute respiratory distress syndrome patients treated with extracorporeal membrane oxygenation. *J Chest Surg.* (2021) 54:36–44. doi: 10.5090/jkcts.20.123
29. Polito A, Dupuis-Lozeron E, Barbaro R, Rimensberger PC. Ventilation parameters before extracorporeal membrane oxygenator and in-hospital mortality in children: a review of the ELSO registry. *ASAIO J.* (2022) 68:281–6. doi: 10.1097/MAT.0000000000001445
30. Prat G, Guinard S, Bizien N, Nowak E, Tonnelier JM, Alavi Z, et al. Can lung ultrasonography predict prone positioning response in acute respiratory distress syndrome patients? *J Crit Care.* (2016) 32:36–41. doi: 10.1016/j.jcrc.2015.12.015
31. Volpicelli G, Lamorte A, Villén T. What’s new in lung ultrasound during the COVID-19 pandemic. *Intensive Care Med.* (2020) 46:1445–8. doi: 10.1007/s00134-020-06048-9
32. Peng QY, Wang XT, Zhang LN. Findings of lung ultrasonography of novel coronavirus pneumonia during the 2019-2020 epidemic. *Intensive Care Med.* (2020) 46:849–50. doi: 10.1007/s00134-020-05996-6

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Wang, Wang, Shi, Dou, Shan, Sun and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.